Please select the option that best describes you:
Do you consider ADT intensification with enzalutamide or abiraterone in patients receiving adjuvant radiation with ADT?
Are there clinical features (post-op PSA, Decipher score, pN+, pT3, etc) that would inform your decision?
Answer from: Radiation Oncologist at Community Practice
I agree with Dr. @Andrew J. Armstrong.One thing to note is ~3% of RADICALS, for example, included pT3b and high grade disease, and almost no patients in the ART vs SRT trials had N+ disease. Was largely GS7 and pT3a population and not the very high risk patients that select surgeons choose to operat...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
The short answer is no. The long answer is that most men even with high risk prostate cancer are presently treated with early salvage RT +/- ADT rather than adjuvant RT +/- ADT given the results of 3 recent phase 3 trials which demonstrated similar results for early salvage radiation vs adjuvant RT,...